Anti-Alpha Synuclein Antibody

Primary Antibody

Alpha Synuclein

Store at 4°C in the dark. Under these conditions, the antibodies should have a shelf life of at least twelve months, provided they remain sterile. For longer term storage, aliquot and freeze to avoid freeze-thaw of the antibody.

10 mg/mL

WB Brain

Detect endogenous levels of alpha-synuclein (SNCA), also known as PARK1, NACP, PARK4, by Western Blot, immunohistochemistry, and immunofluorescence using this highly-validated chicken anti-alpha-synuclein antibody.

Alpha-synuclein (SNCA), also known as PARK1, NACP, PARK4, is a member of the synuclein family, which also includes beta- and gamma-synuclein. Alpha-synuclein is a highly-conserved protein known to be abundant in neurons and especially presynaptic terminals where it serves multiple roles including regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Functionally, alpha synuclein has been implicated in synaptic plasticity (Liu 2004) and the assembly of snare complexes (Burre 2010) and it is known to be associated with various neuropathologies including Parkinson's Disease, Lewy Body Dementia, and Alzheimer's Disease, where it forms insoluble protein aggregates. Early studies of amyloid deposits in the brains of Alzheimer's patients revealed two previously uncharacterized peptides in addition to the amyloid beta fragment (Ueda 1993), both of which were found to correspond to alpha-synuclein (SNCA). Later studies confirmed that aggregated alpha-synuclein proteins are present in brain lesions (Lewy bodies) that are hallmarks of neurodegenerative synucleinopathies and that alpha synuclein likely plays a role in the pathogenesis of Parkinson's disease, Lewy body dementia, and Alzheimer’s disease among other neuropathologies. The SNCA antibody was raised against full-length human alpha synuclein and recognizes endogenous levels of alpha synuclein in brain by Western blot and immunohistochemistry.

Polyclonal

1:100-1:500

Full-length human alpha-synuclein (UniProtKB - P37840) produced in E.Coli.

IgY Fraction

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca2+ release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:30404828). Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:20798282). Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:26442590).

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.